Physician and Patient Safety Act
Summary
The Physician and Patient Safety Act (HR3413) is an early-stage bill that mandates due process procedures for physicians before hospitals can restrict staff privileges. The bill contains no direct funding, is referred to committee with only 6 cosponsors, and carries negligible near-term market impact for the healthcare sector.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR3413 is pure regulatory mandate with zero funding — no direct money trail for investors to follow.
- 2.Bill has not moved past committee referral in 11 months; companion bill also stalled in Senate.
- 3.If enacted, hospital operators ($HCA, $UHS) face minor administrative cost friction, but impact is immaterial to earnings.
- 4.No listed physician or healthcare services company has material revenue exposure to this procedural change.
Market Implications
No actionable market implications. This bill does not alter reimbursement rates, coverage mandates, drug pricing, or any revenue driver for publicly traded healthcare companies. Hospital operators $HCA and $UHS would face negligible incremental compliance costs. Investors should monitor for unexpected movement (committee markup, inclusion in must-pass health legislation) but current baseline expectation is that HR3413 dies in committee.
Full Analysis
-
What happened: HR3413 was introduced in the House on May 14, 2025 by Rep. Ruiz (D-CA) and referred to the House Committee on Energy and Commerce. The bill has 6 cosponsors and an identical companion bill (S1767) in the Senate. As of today (April 30, 2026), the bill remains in committee with no further action — it is stalled in early stage.
-
The money trail: There is zero funding authorization or appropriation in this bill. It is a pure regulatory mandate — it instructs HHS to issue regulations requiring hospitals to provide fair hearings and appellate review before terminating or restricting physician staff privileges. No federal dollars flow. No tax credits, grants, or procurement programs are created.
-
Structural winners and losers: This is not a market-moving bill. Hospitals ($HCA, $UHS) face modest operational friction from additional administrative and legal procedures, but the cost is immaterial relative to their revenue bases (HCA's 2025 revenue ~$70B; UHS ~$16B). Physician staffing companies ($AMN, $CHG Healthcare private) could see minor benefits if the due-process protections make hospital employment less desirable, but this is speculative and not grounded in bill text. No clear winners.
-
Timeline: The bill requires HHS to issue final regulations within 18 months of enactment. However, the bill has not advanced out of committee in nearly a year. Without substantial committee leadership sponsorship or a broader legislative vehicle, passage in this Congress is unlikely.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Regulatory mandate requiring hospitals to provide fair hearing and appellate review before restricting physician staff privileges
Who must act
Hospitals that have granted medical staff privileges to physicians, including HCA Healthcare facilities
What happens
Operational cost increase from establishing and administering hearing/appellate review processes; potential delay in removing underperforming physicians from staff
Stock impact
HCA operates ~180 hospitals and ~2,300 care sites; each facility must now institute due-process hearings before restricting physician privileges, adding legal and administrative overhead. No direct revenue impact, but increased operational friction.
What the bill does
Regulatory mandate requiring hospitals to provide fair hearing and appellate review before restricting physician staff privileges
Who must act
Hospitals that have granted medical staff privileges to physicians, including Universal Health Services facilities
What happens
Operational cost increase from establishing and administering hearing/appellate review processes; potential delay in removing underperforming physicians from staff
Stock impact
UHS operates ~330 acute care hospitals and behavioral health facilities; each must implement due-process procedures before restricting privileges. Increased legal and administrative costs, no revenue impact.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
CAPEX & D SQUARE, A JOINT VENTURE LLC: $23.2M Department of Veterans Affairs Contract
Veterans’ Assuring Critical Care Expansions to Support Servicemembers (ACCESS) Act of 2025
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt".
SPREZZATURA MANAGEMENT CONSULTING, LLC: $23.2M Department of Veterans Affairs Contract
Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act of 2025
To amend title XVIII of the Social Security Act to prevent hospitals or skilled nursing facilities that are owned by certain firms from participating in the Medicare program.
CHOICE for Veterans Act of 2025
Hospital Transparency Compliance Enforcement Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →